D Western Therapeutics Institute : FY12/22 Financial Results Briefing Materials
February 12, 2023
Share
FY12/22
Financial Results Briefing Materials
February 13, 2022
D. Western Therapeutics Institute, Inc.
Stock Code: 4576
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
Table of Contents
FY12/22 Financial Results
Progress of Business in FY12/22
FY12/23 Forecast
(Reference) Business Overview
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
2
1. FY12/22 Financial Results
January 1-December 31, 2022
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
3
Consolidated Statement of Income (YoY comparison)
726
(JPYmn)
565
414
448
469
316
249
256
20
27
Loss attributable to
Net sales
Cost of sales SG&A expenses(R&D expenses)
(Other)
Operating loss
Ordinary loss
owners of parent
(148)
(171)
(159)
FY12/21
FY12/22
(305)
(295)
(429)
Net sales
Royalty revenue grew 30.1% YoY, because sales of DW-1002 increased 22.2% YoY in Europe, US, and Canada, with a favorable forex impact (+7.8% YoY).
Net sales rose 8.1% YoY, underpinned by milestone revenue accompanying the start of domestic Phase I study of DW- 1001 and receiving payment on transfer of exclusive enforcement rights to subsidiary JIT's corneal endothelium therapeutic agents.
R&D expenses
R&D expenses rose 48.5% YoYdue to increased spending on development of H-1337 (Phase IIb study in the US) and DWR-2206.
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
4
Consolidated Statement of Income (vs. full-year forecast)
(JPYmn)
FY12/21
FY12/22
FY results
FY results
YoY change
FY forecast
FY forecast
% of initial
Primary factors
(out Feb.10)
(out Nov.18)
forecast
• Royalty revenue from DW-1002 far exceeded initial
Net sales
414
448
33
370
440
121.1％
forecast
• Received one-time payment for transfer of exclusive
enforcement rights to subsidiary JIT's corneal
endothelium therapeutic agents.
SG&A expenses
565
726
160
R&D expenses
316
469
153
790
Undisclosed
59.4％
• Reduced due to the development cost of H-1337
being lower than expected
Other SG&A
249
256
7
expenses
Operating loss
(171)
(305)
(134)
(690)
(400)
－
Ordinary loss
(159)
(295)
(136)
(700)
(390)
－
Loss attributable
(148)
(429)
(280)
(670)
(380)
－
to owners of
parent
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
D.Western Therapeutics Institute Inc. published this content on 13 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2023 08:56:11 UTC.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
